# Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

> **NCT04599634** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Lymphoma
- B-Cell Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax
- **DRUG:** Magrolimab
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Prednisone/prednisolone
- **DRUG:** Methylprednisolone
- **DIAGNOSTIC_TEST:** CT Scan chest/abdomen/pelvis
- **DIAGNOSTIC_TEST:** MRI
- **DIAGNOSTIC_TEST:** 18-FDG-PET
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Marrow Aspiration

## Key facts

- **NCT ID:** NCT04599634
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-16
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-06-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599634, "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04599634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*